Insulet Corporation
Every calculator, already run for PODD
Open the full toolkit →You have the numbers on PODD. Get the argument.
A written report on which of these readings actually decide the outcome for Insulet Corporation, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
25 analysts covering PODDAnalyst Price Target Disagreement for Insulet Corporation
Wall Street's bull case implies +107% from the current price; the bear case implies +8%. A 98% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for PODD
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provide…
PODD — frequently asked
Is PODD a buy right now?
Wall Street's consensus rating on Insulet Corporation is Buy across 25 analysts, with a mean price target of $171.91 (+29% vs. the current $133.11). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is PODD overvalued?
PODD trades at 25.5x trailing earnings, against a DCF fair value of $68 per share. The current price implies 15% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is PODD's next earnings date?
Insulet Corporation is next scheduled to report earnings around Nov 5, 2026. A full PODD research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Insulet Corporation?
Analysts covering Insulet Corporation (PODD) range from a bear-case target of $144.00 to a bull-case high of $275.00, with a mean consensus target of $171.91 across 22 analysts. The spread of $131.00 (98% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Insulet Corporation against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Insulet Corporation
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full PODD research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Insulet Corporation, in minutes. 3 free reports included with every account — no credit card required.